메뉴 건너뛰기




Volumn 103, Issue 7, 2010, Pages 993-1000

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours

Author keywords

advanced solid tumours; combination; irinotecan; pharmacokinetics; sunitinib

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; IRINOTECAN; SU 012662; SUNITINIB; UNCLASSIFIED DRUG; CAMPTOTHECIN; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

EID: 77957220381     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605852     Document Type: Article
Times cited : (15)

References (33)
  • 1
    • 78650874372 scopus 로고    scopus 로고
    • SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer
    • Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2: 471-478
    • (2003) Mol Cancer Ther , vol.2 , pp. 471-478
    • Abrams, T.J.1    Lee, L.B.2    Murray, L.J.3    Pryer, N.K.4    Cherrington, J.M.5
  • 4
    • 77957244953 scopus 로고    scopus 로고
    • Camptosar
    • Camptosar (2008) http://media.pfizer.com/files/products/uspi-camptosar. pdf
    • (2008)
  • 5
    • 54049120234 scopus 로고    scopus 로고
    • Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: To test or not to test, that is the question
    • Deeken JF, Slack R, Marshall JL (2008) Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer 113: 1502-1510
    • (2008) Cancer , vol.113 , pp. 1502-1510
    • Deeken, J.F.1    Slack, R.2    Marshall, J.L.3
  • 11
    • 0037364658 scopus 로고    scopus 로고
    • Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer
    • DOI 10.1200/JCO.2003.08.058
    • Fuchs CS, Moore MR, Harker G, Villa L, Rinaldi D, Hecht JR (2003) Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21: 807-814 (Pubitemid 46606439)
    • (2003) Journal of Clinical Oncology , vol.21 , Issue.5 , pp. 807-814
    • Fuchs, C.S.1    Moore, M.R.2    Harker, G.3    Villa, L.4    Rinaldi, D.5    Hecht, J.R.6
  • 13
    • 50149083259 scopus 로고    scopus 로고
    • Pharmacogenetics in colorectal cancer: A systematic review
    • Funke S, Brenner H, Chang-Claude J (2008) Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 9: 1079-1099
    • (2008) Pharmacogenomics , vol.9 , pp. 1079-1099
    • Funke, S.1    Brenner, H.2    Chang-Claude, J.3
  • 14
    • 34248173883 scopus 로고    scopus 로고
    • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200
    • Giantonio BJ, Catalano PJ, Meropol NJ, ODwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson III AB (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25: 1539-1544
    • (2007) J Clin Oncol , vol.25 , pp. 1539-1544
    • Giantonio, B.J.1    Catalano, P.J.2    Meropol, N.J.3    Odwyer, P.J.4    Mitchell, E.P.5    Alberts, S.R.6    Schwartz, M.A.7    Benson Iii, A.B.8
  • 16
    • 36849018991 scopus 로고    scopus 로고
    • Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer
    • Gravalos C, Cassinello J, Fernandez-Ranada I, Holgado E (2007) Role of tyrosine kinase inhibitors in the treatment of advanced colorectal cancer. Clin Colorectal Cancer 6: 691-699 (Pubitemid 350221366)
    • (2007) Clinical Colorectal Cancer , vol.6 , Issue.10 , pp. 691-699
    • Gravalos, C.1    Cassinello, J.2    Fernandez-Ranada, I.3    Holgado, E.4
  • 19
    • 55049136730 scopus 로고    scopus 로고
    • Targeted therapies for metastatic renal cell carcinoma: An overview of toxicity and dosing strategies
    • Hutson TE, Figlin RA, Kuhn JG, Motzer RJ (2008) Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 13: 1084-1096
    • (2008) Oncologist , vol.13 , pp. 1084-1096
    • Hutson, T.E.1    Figlin, R.A.2    Kuhn, J.G.3    Motzer, R.J.4
  • 22
    • 57349138859 scopus 로고    scopus 로고
    • Hypertension and proteinuria: A class-effect of antiangiogenic therapies
    • Launay-Vacher V, Deray G (2009) Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 20: 81-82
    • (2009) Anticancer Drugs , vol.20 , pp. 81
    • Launay-Vacher, V.1    Deray, G.2
  • 23
    • 34247849335 scopus 로고    scopus 로고
    • Target practice: Lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer
    • DOI 10.1634/theoncologist.12-4-443
    • Los M, Roodhart JM, Voest EE (2007) Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 12: 443-450 (Pubitemid 46698722)
    • (2007) Oncologist , vol.12 , Issue.4 , pp. 443-450
    • Los, M.1    Roodhart, J.M.L.2    Voest, E.E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.